Cigna Wegovy Prior Authorization: Navigating Evernorth and Express Scripts

Successfully managing Cigna Wegovy prior authorization requires a precise understanding of the payer's specific requirements and submission channels. Klivira streamlines this complex process, ensuring timely approvals for your patients.

For revenue cycle directors, prior authorization coordinators, and IT integration leads, navigating specialty drug PAs can be a significant operational burden. Wegovy, a GLP-1 receptor agonist indicated for chronic weight management, frequently triggers prior authorization requirements under Cigna Healthcare plans. This guide outlines the specific pathways and criteria for securing approval.

Understanding Wegovy and Cigna Healthcare's Coverage Policies

Wegovy (semaglutide) is a GLP-1 receptor agonist manufactured by Novo Nordisk, approved for chronic weight management. Given its classification and indication, Cigna Healthcare typically requires prior authorization to verify medical necessity. Common PA reasons include confirming BMI thresholds, documenting completion of prior lifestyle/nutrition programs, and evaluating benefit exclusions.

Navigating Cigna's Prior Authorization Channels for Wegovy

For pharmacy-benefit drugs like Wegovy, prior authorization submissions for Cigna Healthcare members are primarily managed by Express Scripts, part of Evernorth, The Cigna Group's health services brand. Express Scripts is the PBM for Cigna's pharmacy benefit. For specialty injectables, Accredo, also under Express Scripts and Evernorth, handles specialty pharmacy PAs, following distinct review pathways.

Wegovy Prior Authorization Submission Pathways for Cigna Healthcare

**ePA Portals:** Express Scripts supports electronic prior authorization (ePA) submissions through industry partners CoverMyMeds and Surescripts for prescriber-initiated workflows.
**Express Scripts Provider PA System:** Direct submission through Express Scripts' dedicated provider portal for pharmacy benefit PAs.
**Accredo Specialty Pharmacy:** For specialty injectables, Accredo manages specific PA processes, which may involve their own provider portal or direct communication channels.

Key Clinical Criteria and Documentation for Wegovy PA with Cigna

Cigna Healthcare publishes specific coverage policies and medical-necessity guidelines on its public provider site. These policies are versioned, dated, and outline the clinical criteria required for Wegovy approval. Providers should prepare documentation verifying BMI thresholds, detailing prior participation in supervised lifestyle or nutrition programs, and addressing any step therapy requirements or formulary considerations specific to Express Scripts' formulary.

Electronic Prior Authorization (ePA) for Wegovy on Cigna Plans

Express Scripts has well-established ePA capabilities, facilitating the electronic exchange of information required for Wegovy prior authorizations. Leveraging platforms like CoverMyMeds and Surescripts for NCPDP SCRIPT standard transactions can significantly reduce manual effort and accelerate the review process. While The Cigna Group participates in the HL7 Da Vinci Project, the primary ePA channels for pharmacy benefits remain through established PBM integrations.

Managing Denials and Appeals for Wegovy with Cigna Healthcare

Common denial reasons for Wegovy PA with Cigna Healthcare include insufficient documentation of medical necessity, failure to meet BMI thresholds, lack of documented prior lifestyle programs, or benefit exclusions. Denials are communicated via X12 277/835 transactions and status updates on CignaforHCP.com. The appeal pathway is documented on the provider portal and in the Cigna Provider Manual, offering options for peer-to-peer reviews for clinical denials and expedited appeals for urgent cases.

Frequently asked questions

What is Wegovy indicated for, and why does Cigna require prior authorization?

Wegovy (semaglutide) is a GLP-1 receptor agonist indicated for chronic weight management. Cigna Healthcare requires prior authorization to ensure medical necessity, verify patient-specific criteria like BMI thresholds, confirm completion of prior lifestyle interventions, and manage benefit consistency.

Which Cigna entity handles Wegovy prior authorizations?

For pharmacy-benefit drugs like Wegovy, prior authorizations for Cigna Healthcare members are managed by Express Scripts, which operates under the Evernorth health services brand. For specialty injectables, Accredo, also part of Evernorth, may be involved.

What are common reasons for Wegovy PA denials by Cigna Healthcare?

Typical denial reasons include insufficient documentation of medical necessity, failure to meet Cigna's specific BMI criteria, lack of documented participation in a prior supervised lifestyle program, non-formulary status on the Express Scripts formulary, or benefit exclusion per the member's plan.

How can I submit a Wegovy prior authorization request to Cigna?

Providers can submit Wegovy prior authorization requests electronically via CoverMyMeds or Surescripts, which integrate with Express Scripts' ePA system. Direct submission through the Express Scripts provider portal is also an option. For specialty pharmacy, Accredo may have its own submission pathways.

What are the typical turnaround times for Wegovy PA with Cigna?

Turnaround times vary based on the plan type and state. For Cigna's Medicare Advantage plans, CMS-0057-F mandates 72-hour standard and 24-hour expedited PA timeframes. For commercial plans, state-specific insurance regulations govern the minimum turnaround times, which Klivira helps track and adhere to.